Mitotane increases the blood levels of hormone-binding proteins
The DOI matches its Crossref record.
Abstract
: In 3 patients with adrenocortical carcinoma the effects of long-term mitotane therapy on the serum levels of three hormone-binding globulins and vitamin D-binding protein were studied. Within the first month of treatment cortisol-binding globulin increased two to three times, in close correlation with sex hormone-binding globulin. The rises in thyroxine-binding globulin and vitamin D-binding protein were considerably less. Elevated cortisol-binding protein appeared to be associated with increased binding of cortisol, whereas the binding of thyroxine and vitamin D remained below normal. Binding proteins returned to normal in 2 patients within a year after mitotane discontinuation. This phenomenon of hormone-binding protein enhancement invalidates the use of total serum hormone levels to monitor the effects of mitotane on endocrine function and could provide an explanation for the increased cortisol substitution requirement during mitotane therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Examples of drugs that increase serum TBG from insignificant to significant degrees, include estrogen (201), tamoxifen (202), raloxifene (203), clofibrate (204), opioids (205), mitotane (206), fluorouracil (207), and capecitabine (208).”
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
“Utility of mitotane levels in following patients on adjuvant therapy (VanSeters & Moolenaar 1991, Haak et al. 1994, Terzolo et al. 2000) Mitotane levels should be obtained during treatment and dose should aim for levels of 14–20 mg/dl if tolerated (see guidelines for mitotane use below).”
BackgroundSurks, M. I., & Sievert, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332507 · Cited by 354
Haak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
“Thus, measurement of total hormone concentrations may give normal results in the presence of clearly impaired bioavailability of free hormones (van Seters & Moolenaar, 1991).”
BackgroundMidnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes.
Yaneva, M., Mosnier-Pudar, H., Dugué, M.-A., Grabar, S., Fulla, Y., & Bertagna, X. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031790 · Cited by 179
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0103 · Cited by 167
“…was previously found www.endocrinology-journals.org Downloaded from Bioscientifica.com at 12/15/2018 10:20:31PM via free access to increase thyroxine-binding globulin (Van Seters & Moolenaar 1991) and to compete with thyroxine for thyroxine-binding globulin sites (Marshall & Tompkins 1968).”
MethodA review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167
Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Biology, clinical characteristics, and management of adrenocortical tumors in children
Rodriguez‐Galindo, C., Figueiredo, B. C., Zambetti, G. P., & Ribeiro, R. C. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20318 · Cited by 146
“Mitotane increases the metabolic clearance of glucocorticoids [68,69], and administration of hydrocortisone plus fludrocortisone allows independent adjustment of glucocorticoid and mineralocorticoid dosage.”
BackgroundNew insights into corticosteroid-binding globulin and glucocorticoid delivery
Henley, D. E., & Lightman, S. L. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.053 · Cited by 115
Nader, N., Raverot, G., Emptoz-Bonneton, A., Déchaud, H., Bonnay, M., Baudin, E., & Pugeat, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2157 · Cited by 89
“Finally, increased serum corticosteroid-binding globulin (CBG) concentrations have also been reported in mitotanetreated patients (13).”
BackgroundResultCorticosteroid-binding globulin: The clinical significance of altered levels and heritable mutations
Gagliardi, L., Ho, J. T., & Torpy, D. J. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.015 · Cited by 88
Zatelli, M. C., Gentilin, E., Daffara, F., Tagliati, F., Reimondo, G., Carandina, G., Ambrosio, M. R., Terzolo, M., & degli Uberti, E. C. (2010) · Endocrinology · doi:10.1210/en.2009-1404 · Cited by 57
“Previously, mitotane has been demonstrated to increase T4-binding globulin (TBG) (15) and to compete with T4 for TBG binding sites (16), but these findings do not explain the changes in thyroid function pattern observed during adjuvant therapy.”
InfluentialMitotane treatment in patients with adrenocortical cancer causes central hypothyroidism
Russo, M., Scollo, C., Pellegriti, G., Cotta, O. R., Squatrito, S., Frasca, F., Cannavò, S., & Gullo, D. (2016) · Clinical Endocrinology · doi:10.1111/cen.12868 · Cited by 36
Metadata
- Authors
- van Seters, A. P., & Moolenaar, A. J.
- Venue
- Acta Endocrinologica
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-05
- Volume
- 124
- Issue
- 5
- Pages
- 526-533
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W1974720607
- Cited by
- 82
- References
- 0
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.